Can targeting CD36 reshape hepatocellular carcinoma immunotherapy? Pilatus Biosciences takes first step
Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.
Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care
ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.
Devonian Health Group advances Thykamine with human liver-on-a-chip data targeting fibrosis in MASH
Devonian Health Group reports human liver-on-a-chip data for Thykamine in MASH. See what this means for fibrosis-focused drug development.
Menopause-specific hair loss enters the clinical spotlight after KilgourMD trial data
KilgourMD’s phase II data challenges how menopause-related hair loss is studied and treated. See what changes and what clinicians will watch next.
Ambient-temperature RNA-ISH enters mainstream pathology as Molecular Instruments expands HCR Pro automation
Discover how Molecular Instruments’ ambient-temperature HCR Pro RNA-ISH on BOND-III could reshape clinical pathology automation and RNA diagnostics.
How Seek Labs’ CRISPR platform could change the economics of avian influenza outbreaks
Seek Labs secures USDA funding for a CRISPR-based avian flu therapeutic. Find out why mutation-resistant platforms may redefine HPAI response.
Starton Therapeutics advances STAR-LLD as delivery innovation in multiple myeloma
Starton Therapeutics advances STAR-LLD in Phase 2a. Explore how continuous lenalidomide delivery could reshape multiple myeloma care.
What Avidity Biosciences Phase 1/2 MARINA results reveal about the future of DM1 drug development
NEJM publication of Avidity Biosciences delpacibart etedesiran data raises new questions for DM1 treatment. Discover what this changes next.
Gilead expands its HIV playbook as lenacapavir moves from niche drug to platform strategy
Gilead’s CROI 2026 data highlight lenacapavir’s evolution into a platform for HIV treatment and prevention. Explore what this changes for clinicians and regulators.
What Omeros Corporation’s OncotoX-AML study reveals about mutation-agnostic AML therapies
Omeros Corporation advances OncotoX-AML after primate data. Explore what this means for AML therapy, risks ahead, and why clinicians are watching closely.